Rutter Charles E, Johung Kimberly L, Yao Xiaopan, Lu Alex Y, Jilaveanu Lucia B, Yu James B, Contessa Joseph N, Kluger Harriet M, Chiang Veronica L S, Bindra Ranjit S
Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06510, USA.
Department of Internal Medicine (Medical Oncology), Yale School of Medicine, New Haven, CT 06510, USA.
J Radiosurg SBRT. 2016;4(2):97-106.
Metastatic melanoma often involves the brain. Radiotherapy is an important treatment of melanoma brain metastases, although melanoma radiosensitivity is considered heterogeneous. Thus, identifying subsets with differential radiosensitivity is essential.
Patients with metastatic melanoma were identified in a prospective stereotactic radiosurgery (SRS) database. Tumor were tested for alterations in B-RAF, N-RAS, and c-KIT. Standardized imaging following SRS was reviewed for recurrence. Differences in local and distant failure were determined using modified Cox proportional hazards models.
102 patients and 1,028 brain metastases were included. N-RAS mutated patients were significantly less likely to develop local recurrence after SRS than wild type patients (HR 0.17, 95% CI 0.04-0.72, p=0.017). B-RAF and c-KIT mutations were not associated with altered rates of local recurrence. Lower local recurrence rates for N-RAS mutated tumors persisted on multivariate analysis (HR 0.18, 95% CI 0.04-0.84p=0.029).
N-RAS mutation is associated with improved local control following SRS. Local recurrence is more common in wild type patients and those with B-RAF or c-KIT mutations. Further research is needed to validate these findings and integrate into practice.
转移性黑色素瘤常累及脑部。放疗是黑色素瘤脑转移的重要治疗方法,尽管黑色素瘤的放射敏感性被认为存在异质性。因此,识别具有不同放射敏感性的亚组至关重要。
在前瞻性立体定向放射外科(SRS)数据库中识别转移性黑色素瘤患者。检测肿瘤的B-RAF、N-RAS和c-KIT改变。回顾SRS后的标准化影像以评估复发情况。使用改良的Cox比例风险模型确定局部和远处失败的差异。
纳入102例患者和1028个脑转移灶。N-RAS突变患者在SRS后发生局部复发的可能性显著低于野生型患者(风险比0.17,95%置信区间0.04-0.72,p=0.017)。B-RAF和c-KIT突变与局部复发率改变无关。多因素分析显示,N-RAS突变肿瘤的局部复发率较低(风险比0.18,95%置信区间0.04-0.84,p=0.029)。
N-RAS突变与SRS后局部控制改善相关。局部复发在野生型患者以及B-RAF或c-KIT突变患者中更常见。需要进一步研究以验证这些发现并将其纳入实践。